Karyopharm Therapeutics is a pharmaceutical firm driven by innovation, dedicated to the exploration, advancement, and commercialization of medications aimed at enhancing the well-being of individuals battling cancer. Established in 2008, our company envisions leading the way in a potential new methodology for treating cancer and other severe illnesses. Our innovative approach to cancer therapy revolves around the inhibition of specific protein export from the nucleus of cancer cells using SINE technology (Selective Inhibition of Nuclear Export). Our primary emphasis is on creating pioneering drugs that hold promise in treating patients with specific blood cancers.
Karyopharm Therapeutics
Headquarters
United States of America